title: Activation of human T lymphocytes by bryostatin.
abstract: The immunologic effects of bryostatin (Bryo), a PKC activator with antineoplastic activity, were assessed and compared to PMA. Bryo induced IL-2R expression on CD4+ and CD8+ human T lymphocytes with a dose response comparable to PMA. However, Bryo induced only a marginal proliferative response as compared with the vigorous response induced by PMA. Bryo mediated functional receptor expression because the proliferative response was enhanced by addition of rIL-2. Furthermore, the proliferative response was inhibited by the relatively specific Ca+, phospholipid-dependent protein kinase (PKC) inhibitor, H-7, indicating a role of PKC in Bryo-induced activation. Addition of the calcium ionophore, ionomycin, to Bryo-stimulated lymphocytes resulted in the production and secretion of IL-2 with a concomitant proliferative response. This effect of the calcium ionophore could be inhibited by cyclosporine with identical results obtained in PMA-stimulated cultures. A most intriguing finding was that Bryo could effectively antagonize PMA-induced T cell proliferation. Although this mechanism of inhibition is unclear, a discussion with respect to differential effects on potential intracellular PKC isoforms is provided. These studies indicated that Bryo has potent immunopotentiating properties that share some similar effects of the phorbol ester, PMA, but offers the additional property of modulating other phorbol ester effects on proliferation.
authors.affiliation: Bone Marrow Transplant Unit, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.
authors.forename: A D
authors.initials: AD
authors.lastname: Hess
authors.forename: M K
authors.initials: MK
authors.lastname: Silanskis
authors.forename: A H
authors.initials: AH
authors.lastname: Esa
authors.forename: G R
authors.initials: GR
authors.lastname: Pettit
authors.forename: W S
authors.initials: WS
authors.lastname: May
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D054713:Bryostatins; D006801:Humans; D007376:Interleukin-2 / Q000096:biosynthesis; D007783:Lactones / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000187:drug effects*; D018942:Macrolides; D011493:Protein Kinase C / Q000378:metabolism; D015375:Receptors, Interleukin-2 / Q000096:biosynthesis; D011990:Receptors, Transferrin / Q000096:biosynthesis; D013601:T-Lymphocytes / Q000276:immunology* / Q000378:metabolism; D013755:Tetradecanoylphorbol Acetate
chemical_list: D000276:Adjuvants, Immunologic; D054713:Bryostatins; D007376:Interleukin-2; D007783:Lactones; D018942:Macrolides; D015375:Receptors, Interleukin-2; D011990:Receptors, Transferrin; C046785:bryostatin 1; D011493:Protein Kinase C; D013755:Tetradecanoylphorbol Acetate